Home Cart Sign in  
Chemical Structure| 103478-62-2 Chemical Structure| 103478-62-2

Structure of Fmoc-N-Me-Leu-OH
CAS No.: 103478-62-2

Chemical Structure| 103478-62-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: Fmoc-N-Me-Leu-OH

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 103478-62-2 ]

CAS No. :103478-62-2
Formula : C22H25NO4
M.W : 367.44
SMILES Code : CC(C)C[C@@H](C(O)=O)N(C(OCC1C2=CC=CC=C2C3=CC=CC=C13)=O)C
Synonyms :
Fmoc-N-Me-Leu-OH
MDL No. :MFCD00151933
InChI Key :BUJQSIPFDWLNDC-FQEVSTJZSA-N
Pubchem ID :7015835

Safety of [ 103478-62-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P305+P351+P338

Computational Chemistry of [ 103478-62-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 27
Num. arom. heavy atoms 12
Fraction Csp3 0.36
Num. rotatable bonds 8
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 104.49
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

66.84 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.68
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

4.56
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

4.37
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

3.22
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.51
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.67

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-4.79
Solubility 0.00593 mg/ml ; 0.0000162 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.69
Solubility 0.000756 mg/ml ; 0.00000206 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-5.37
Solubility 0.00156 mg/ml ; 0.00000426 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

Yes
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.3 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<3.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.97

Application In Synthesis of [ 103478-62-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 103478-62-2 ]

[ 103478-62-2 ] Synthesis Path-Downstream   1~41

  • 1
  • [ 29022-11-5 ]
  • [ 103478-62-2 ]
  • [ 108-24-7 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • Ac-Lys-NMePhe-Gly-NMeLeu-NH2 [ No CAS ]
  • 2
  • [ 2439-37-4 ]
  • [ 103478-62-2 ]
  • [ 71989-33-8 ]
  • [ 77128-73-5 ]
  • (S)-2-[((S)-2-[(S)-3-tert-Butoxy-2-((S)-2-dimethylamino-4-methyl-pentanoylamino)-propionyl]-methyl-amino}-4-methyl-pentanoyl)-methyl-amino]-3-phenyl-propionic acid [ No CAS ]
  • 3
  • [ 2439-37-4 ]
  • [ 103478-62-2 ]
  • [ 71989-33-8 ]
  • [ 77128-73-5 ]
  • [ 873951-99-6 ]
  • 4
  • [ 2439-37-4 ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [ 111061-56-4 ]
  • [ 873951-96-3 ]
  • 5
  • (S)-2-[((S)-2-[(S)-3-tert-Butoxy-2-((S)-2-dimethylamino-4-methyl-pentanoylamino)-propionyl]-methyl-amino}-4-methyl-pentanoyl)-methyl-amino]-3-phenyl-propionic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [ 111061-56-4 ]
  • N,N-dimethylleucine [ No CAS ]
  • [ 873951-99-6 ]
  • 6
  • [ 29022-11-5 ]
  • [ 103478-62-2 ]
  • [ 108-24-7 ]
  • [ 71989-28-1 ]
  • [ 103478-58-6 ]
  • [ 138775-22-1 ]
  • [ 960324-14-5 ]
  • 7
  • [ 103478-62-2 ]
  • [ 108-24-7 ]
  • [ 71989-28-1 ]
  • [ 103478-58-6 ]
  • [ 77128-70-2 ]
  • [ 138775-22-1 ]
  • [ 960324-16-7 ]
  • 8
  • C6H12NO2Pol [ No CAS ]
  • [ 35661-60-0 ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [ 84624-17-9 ]
  • [ 1252661-13-4 ]
  • 9
  • (2S,3R)-2((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylpentanoic acid [ No CAS ]
  • C27H34NO7PolSi [ No CAS ]
  • [ 122889-11-6 ]
  • [ 103478-62-2 ]
  • C50H68N3O12PolSi [ No CAS ]
  • 10
  • [ 35661-60-0 ]
  • [ 118904-37-3 ]
  • [ 103478-62-2 ]
  • [ 101555-63-9 ]
  • [ 170642-27-0 ]
  • [ 150256-42-1 ]
  • H2N-L-Leu-D-allo-Ile-Ant-L-Pip-L-MeLeu-D-Aba-OH [ No CAS ]
  • 11
  • [ 35661-39-3 ]
  • Me<SUB>2</SUB>Val-HIV-OH [ No CAS ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 53267-93-9 ]
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 117106-20-4 ]
  • [ 138775-22-1 ]
  • C80H122N10O19 [ No CAS ]
  • 12
  • [ 35661-39-3 ]
  • Me<SUB>2</SUB>Val-HIV-OH [ No CAS ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 53267-93-9 ]
  • [ 103478-62-2 ]
  • [ 117106-20-4 ]
  • (2R)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}propanoic acid [ No CAS ]
  • [ 138775-22-1 ]
  • C80H122N10O19 [ No CAS ]
  • 13
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • 2-chlorotrityl chloride polystyrene resin [ No CAS ]
  • [ 17407-55-5 ]
  • [ 68858-20-8 ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C62H103N10O16Pol [ No CAS ]
  • 14
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 17407-55-5 ]
  • [ 68858-20-8 ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C78H116N10O18 [ No CAS ]
  • 15
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C69H98N8O16 [ No CAS ]
  • 16
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C62H88N8O13 [ No CAS ]
  • 17
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C67H97N9O15 [ No CAS ]
  • 18
  • Alloc-Me-Ala [ No CAS ]
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C55H75N7O12 [ No CAS ]
  • 19
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C54H74N6O12 [ No CAS ]
  • 20
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C61H87N7O13 [ No CAS ]
  • C61H87N7O13 [ No CAS ]
  • 21
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C49H65N5O10 [ No CAS ]
  • 22
  • [ 35661-39-3 ]
  • [ 103478-62-2 ]
  • [ 143674-78-6 ]
  • [ 138775-22-1 ]
  • C44H56N4O8 [ No CAS ]
  • 23
  • trityl chloride polystyrene resin [ No CAS ]
  • [ 1240507-79-2 ]
  • [ 35737-10-1 ]
  • [ 103478-62-2 ]
  • [ 71989-23-6 ]
  • [ 138775-22-1 ]
  • C61H90N5O10PolSi [ No CAS ]
  • 24
  • trityl chloride polystyrene resin [ No CAS ]
  • [ 1240507-79-2 ]
  • [ 35737-10-1 ]
  • [ 35661-40-6 ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • C64H88N5O10PolSi [ No CAS ]
  • 25
  • trityl chloride polystyrene resin [ No CAS ]
  • [ 1240507-79-2 ]
  • [ 35737-10-1 ]
  • [ 103478-62-2 ]
  • [ 71989-23-6 ]
  • [ 77128-73-5 ]
  • C64H88N5O10PolSi [ No CAS ]
  • 26
  • trityl chloride polystyrene resin [ No CAS ]
  • [ 1240507-79-2 ]
  • [ 35737-10-1 ]
  • [ 35661-40-6 ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • C67H86N5O10PolSi [ No CAS ]
  • 27
  • [ 35661-60-0 ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [ 94744-50-0 ]
  • C50H69N7O8 [ No CAS ]
  • 28
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • C49H91N9O10 [ No CAS ]
  • 29
  • [ 27219-07-4 ]
  • Fmoc-Ser(octyl)-OH [ No CAS ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [N-aminopentanoyl-Ser3(octyl)-(Me)Phe4-(Me)Leu5]-ghrelin(3-5)-amide [ No CAS ]
YieldReaction ConditionsOperation in experiment
Fmoc-amide resin (0.40 g, 0.25 mmol) was placed in a reaction vessel equipped with a glass filter, and 15 mL of 20percent piperidine in NMP was added thereto and shaken for 20 minutes, thus removing the Fmoc group. Thereafter, 15 mL NMP, 1.0 mmol (4 equivalents) of Fmoc-MeLeu-OH, 1.0 mmol (4 equivalents) of TBTU, 1.0 mmol (4 equivalents) of HOBt and 1.0 mmol (4 equivalents) of DIPEA were added thereto and shaken for 1 hour to condense the Fmoc-MeLeu. Thereafter, the peptide chain was extended by repeatedly carrying out removal of Fmoc group by 20percent piperidine and condensation of Fmoc-amino acid (3 equivalents) by bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (3 equivalents) in the presence of 2.25 mmol (9 equivalents) of DIPEA. The conclusion of the condensation reaction was confirmed by deprotecting a small amount of the resin with TFA and examining it by HPLC and mass spectrometry (MS). After Boc-NH?(CH2)4?CO-Ser (O?C8H17)-MePhe-MeLeu-resin was obtained, this resin was treated with TFA for 30 minutes, whereby the resin was cleaved to de-protect the peptide. After the TFA was evaporated, the peptide was washed with ether (Et2O) to give 120 mg NH2?(CH2)4?CO-Ser(C8H17)-MePhe-MeLeu-NH2. This product was applied to YMC-Pack ODS-A (C18, 20 mm×250 mm) and eluted with a linear gradient (flow rate: 10 mL/min.) for 60 minutes of 0 to 54percent acetonitrile in 0.1percent trifluoroacetic acid. The desired fractions were collected and lyophilized to give 70 mg of the desired product. After this derivative was hydrolyzed with propionic acid-HCl (50/50) at 150° C. for 2 hours, the amount of the peptide was quantified using the ratio of the peak area of aminopentanoic acid detected in the amino acid analyzer to that of 10 nmol aminopentanoic acid as a standard. ESI-MS [M+H]; 604.5 (theoretical: 603.8), detected amino acids after hydrolysis with propionic acid?HCl (50/50) at 150° C. for 2 hours: Ser, Ape.
  • 30
  • [ 455-40-3 ]
  • [ 71989-31-6 ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • 1-[(1,1-dimethylethoxy)carbonyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-tryptophan [ No CAS ]
  • [ 107-92-6 ]
  • [ 204316-32-5 ]
  • (2S)-1-[(2S)-2-[[(2S)-2-[butanoyl(methyl)amino]-3-(1H-indol-3-yl)propanoyl]methylamino]-4-methylpentanoyl]-N-[(1S)-1-[[(1S)-3-[(3,5-difluorobenzoyl)amino]-1-(hydroxycarbamoyl)propyl]carbamoyl]-2-methylbutyl]-N-methyl-pyrrolidine-2-carboxamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
1.5 eq of commercially available Fmoc-NH-OH and DIEA (10 eq) are added to the 2-chlorotrityl resin in 2 mL DCM. The mixture is intermittently stirred manually during 24h. After that, 0.5 mL/g of MeOH are added to the reaction mixture to cap the remaining reactive points of the resin. After 15 minutes, the solution is filtered off and the resin is washed thoroughly with DCM, DMF and MeOH. Fmoc removal is achieved by treating the resin with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15'). For the coupling of Na-Fmoc-NY-alloc-L-2,4-diaminobutyric acid (Fmoc-L-Dab(alloc)-OH), 3 eq of the amino acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure dissolved in a small amount of DMF and premixed for 2 minutes. The resulting mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. To extent of the reaction is monitored using the Kaiser test. The Fmoc group is then removed by treatments with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15 '). After that, Fmoc- N-methyl-L-iso leucine (Fmoc-NMe-L-Ile-OH) moiety is attached, for that purpose 3 eq of the amino acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure are dissolved in a small amount of DMF and premixed for 2 minutes. The resulting mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. The extent of the reaction is monitored using the Kaiser test. The Fmoc group is then removed by treatments with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15 '). After that, Fmoc- L-Proline (Fmoc-L-Pro-OH) moiety is attached, for that purpose 3 eq of the amino acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure are dissolved in a small amount of DMF and premixed for 2 minutes. The resulting the mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. The extent of the reaction is monitored using the Kaiser test. The Fmoc group is then removed by treatments with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15') and additional treatment with a mixture of piperidine/DBU/toluene/DMF (5:5:20:70) (1 x 5'). After that, Fmoc-N- methyl-L-leucine (Fmoc-NMeLeu-OH) moiety is attached, for that purpose 3 eq of the amino acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure are dissolved in a small amount of DMF and premixed for 2 minutes. The resulting mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. The extent of the reaction is monitored using the Kaiser test. The Fmoc group is then removed by treatments with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15'). After that, Na- Fmoc-N(in)-Boc-N-methyl-L-tryptophan (Fmoc-NMe-L-Trp(Boc)-OH) moiety is attached, for that purpose 3 eq of the amino acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure are dissolved in a small amount of DMF and premixed for 2 minutes. The resulting mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. The extent of the reaction is monitored using the Kaiser test. The Fmoc group is then removed by treatments with 20% piperidine in DMF (1 x 5', 1 x 10' and 1 x 15'). Butiric acid is coupled to the tryptophan moiety by adding to the resin 3 eq of the acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure are dissolved in a small amount of DMF and premixed for 2 minutes. The resulting the mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. Then the reaction is filtered off and the resin is rinsed thoroughly with DMF and DCM. The extent of the reaction is monitored using the chloranil test. For the removal of the Alloc group, 10 eq of phenylsilane in DCM are added to the resin while N2 is bubbled through the mixture. Then, 0.1 eq of Pd(PPli3)4 are added maintaining the N2 bubbling while mixing everything well. Then the reaction vessel is sealed and shaken for 15 minutes. After this time, the reaction is filtered and the resin washed thoroughly. The same treatment is repeated two more times. After the last treatment, the resin is washed thoroughly with DCM, MeOH and DMF. For the coupling of the 3,5-difluorobenzoic acid on the side chain of the diaminoethyl moiety, 3 eq of said acid, 3 eq of the coupling agent DIC and 3 eq of oxyma pure dissolved in a small amount of DMF and premixed for 2 minutes. The resulting mixture is added to the resin and the reaction is allowed to proceed for 60 minutes. After this time, the resin is washed with DMF and DCM and the extent of the reaction is monitored the Kaiser test. For the cleavage of the peptide, the resin is washed several times with DCM and dried by suction. The peptide is cleaved from the resin by adding a solution of DCM/TFA (95:5), the mixture is allowed to react for 15 min. Then the reaction mixture is filtered and the resin rinsed with DCM. This cleavage procedure is repeated twice. All the filtrates are pooled and the solvent is evaporated under vacuum, yielding example 14. The compound is purified using reverse-phase chromatography.
  • 31
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • C25H22NO4Pol [ No CAS ]
  • [ 103478-62-2 ]
  • [ 103478-58-6 ]
  • [ 84624-17-9 ]
  • [ 138775-22-1 ]
  • C60H103N10O14Pol [ No CAS ]
  • 32
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • C25H22NO4Pol [ No CAS ]
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 103478-58-6 ]
  • N-Fmoc-N-methyl-D-valine [ No CAS ]
  • [ 138775-22-1 ]
  • C59H101N10O12Pol [ No CAS ]
  • 33
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • C25H22NO4Pol [ No CAS ]
  • (R)-2-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methylbutanoyl)oxy)-3-methylbutanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 138775-22-1 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(tert-butoxy)propanoic acid [ No CAS ]
  • C62H106N9O14Pol [ No CAS ]
  • 34
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • C25H22NO4Pol [ No CAS ]
  • (R)-2-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methylbutanoyl)oxy)-3-methylbutanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(tert-butoxy)propanoic acid [ No CAS ]
  • C66H114N9O15Pol [ No CAS ]
  • 35
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • C25H22NO4Pol [ No CAS ]
  • (R)-2-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methylbutanoyl)oxy)-3-methylbutanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 138775-22-1 ]
  • Nα-Fmoc-Nε-Boc-Nα-methyl-L-lysine [ No CAS ]
  • C66H113N10O15Pol [ No CAS ]
  • 36
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • Fmoc-N-Me-Val-HIV-OH [ No CAS ]
  • (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • C25H22NO4Pol [ No CAS ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • C60H102N9O15Pol [ No CAS ]
  • 37
  • N-Fmoc-N-methyl-L-threonine [ No CAS ]
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • C25H22NO4Pol [ No CAS ]
  • (R)-2-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methylbutanoyl)oxy)-3-methylbutanoic acid [ No CAS ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • C60H102N9O15Pol [ No CAS ]
  • 38
  • [ 35661-39-3 ]
  • (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
  • Fmoc-N-Me-Val-HIV-OH [ No CAS ]
  • Fmoc-D-allo-N-Me-Thr-OH [ No CAS ]
  • C25H22NO4Pol [ No CAS ]
  • [ 103478-62-2 ]
  • [ 138775-22-1 ]
  • C60H102N9O15Pol [ No CAS ]
  • 39
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 77128-73-5 ]
  • [ 77128-70-2 ]
  • H-MeAla-MeLeu-MePhe-MeGly-OH [ No CAS ]
  • 40
  • [ 29022-11-5 ]
  • [ 103478-62-2 ]
  • [ 84000-07-7 ]
  • [ 77128-73-5 ]
  • H-MeAla-MeLeu-MePhe-Gly-OH [ No CAS ]
  • 41
  • H-N(Phenethyl)-POL [ No CAS ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • C25H35N3O2 [ No CAS ]
 

Historical Records

Categories